Hemostasis Today
NewsFeed
Headlines Hematology Health Medicine VTE ASH Plasma Donation
July, 2026
July 2026
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
Yvette Fairfax: Wiskott-Aldrich Gene Therapy Changes Immunity, but Affordability May Determine Survival
Yvette Fairfax/LinkedIn
Jun 7, 2026, 18:24

Yvette Fairfax: Wiskott-Aldrich Gene Therapy Changes Immunity, but Affordability May Determine Survival

Yvette Fairfax, Shareholder of KOELIS, shared a post on LinkedIn:

“The approval of the first gene therapy for Wiskott-Aldrich syndrome is a profound milestone for families facing a disorder linked to immune dysfunction, bleeding risk, and repeated infections.

For affected children, this kind of therapy is not just an incremental medical improvement. It has the potential to reduce hospital crises, improve stability, and reshape daily life in a much more fundamental way.But the controversy begins right after celebration.

Gene therapies often represent the best of science and the hardest realities of healthcare economics at the same time. A breakthrough can be medically transformative and still remain financially out of reach for families trapped in slow reimbursement systems or unequal access pathways.

In the U.S., UK, and Canada, rare-disease medicine keeps exposing the same structural tension: scientific innovation moves faster than fair access. If a one-time treatment can prevent years of suffering, complications, and repeated medical costs, waiting too long to fund it may be both unjust and inefficient.

Should public systems approve payment earlier for these therapies instead of forcing families through exhausting access battles first?”

Yvette Fairfax

Stay updated with Hemostasis Today.

bleeding disorders Blood Canada Gene therapy Health Hematology Hemostasis News Hemostasis Today Medicine U.S. UK Wiskott-Aldrich Syndrome Yvette Fairfax
NewsFeed